Home » Stocks » CNCE

Concert Pharmaceuticals, Inc. (CNCE)

Stock Price: $10.51 USD -0.41 (-3.75%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
Pre-market: $10.50 -0.01 (-0.10%) Jan 22, 7:00 AM
Market Cap 322.12M
Revenue (ttm) 7.91M
Net Income (ttm) -72.86M
Shares Out 31.55M
EPS (ttm) -2.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $10.51
Previous Close $10.92
Change ($) -0.41
Change (%) -3.75%
Day's Open 11.15
Day's Range 10.50 - 11.35
Day's Volume 210,741
52-Week Range 5.98 - 13.07

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 2 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will present at the Stifel Healthcare Conference and participate in a fireside chat at the Jefferies London Healthcare Conference.

Seeking Alpha - 2 months ago

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will host a conference call and webcast today at 8:30 a.m. ET to provide an update on the Company and discuss third quarter 2020 resu...

Business Wire - 2 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert initiated THRIVE-AA1, a Phase 3 study to evaluate the efficacy and safety of CTP-543 in adults with moderate to severe alopecia areata.

Business Wire - 2 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert presented initial data from an ongoing long-term, open-label extension study of CTP-543 in patients with alopecia areata at EADV.

Business Wire - 2 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will host a conference call and webcast on November 5, at 8:30 AM to discuss third quarter financial results and provide a business u...

Business Wire - 3 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Key findings of the survey show that patients with alopecia areata suffer significantly increased burden of illness.

Business Wire - 3 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--The EADV presentation will highlight new CTP-543 data from an ongoing open label extension study in patients with moderate to severe alopecia...

Business Wire - 3 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert completed enrollment in its Phase 2 trial evaluating CTP-692 as an adjunctive treatment in patients with schizophrenia.

Business Wire - 4 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--In September, Concert will participate virtually at the H.C.

Business Wire - 5 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert to participate in a fireside chat with Jason Butler at The JMP Securities CNS Forum.

Seeking Alpha - 5 months ago

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Concert (CNCE) delivered earnings and revenue surprises of 39.71% and 63770.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 5 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will host a conference call and webcast today at 8:30 a.m.

Zacks Investment Research - 5 months ago

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 5 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert Pharmaceuticals, Inc.

Forbes - 6 months ago

Today also marked the beginning of bank earnings season, with JPMorgan beating expectations on both earnings and revenues driven by a surge in trading revenue amid the market’s volatile second...

Other stocks mentioned: CRDF, IDN, REPH, VRTV
Forbes - 6 months ago

Shortly after markets jumped in response to June's jobs report, gains were erased as a surge in coronavirus cases was reported across the country. This puts a damper on the economy's recovery.

Other stocks mentioned: ALPN, MRAM, PIXY, SGBX
Zacks Investment Research - 6 months ago

Concert (CNCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 6 months ago

Is (CNCE) Outperforming Other Medical Stocks This Year?

Benzinga - 6 months ago

Shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) fell by 1.8% from the previous closing price.

Zacks Investment Research - 7 months ago

Small Drug Industry Prospects Bright Amid Coronavirus Gloom

Other stocks mentioned: ATXI, MEIP, NERV, OCUL
Zacks Investment Research - 8 months ago

Concert Pharmaceuticals (CNCE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Seeking Alpha - 8 months ago

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Concert (CNCE) delivered earnings and revenue surprises of 5.41% and -65.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 8 months ago

Concert (CNCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 9 months ago

Concert Pharmaceuticals (CNCE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

Seeking Alpha - 10 months ago

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Concert Pharmaceuticals, Inc (CNCE) CEO Roger Tung on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Concert (CNCE) delivered earnings and revenue surprises of 15.29% and -97.14%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 1 year ago

Shares fall hard after a late-stage trial comes up short.

Seeking Alpha - 1 year ago

Concert announced that it had achieved the primary endpoint in the phase 2 study using CTP-543 to treat patients with alopecia areata.

Seeking Alpha - 1 year ago

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Concert (CNCE) delivered earnings and revenue surprises of 15.22% and -83.67%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share...

Seeking Alpha - 1 year ago

Shares at one point tripled shortly after my original article but have lost around half their value since my last update piece.

Seeking Alpha - 1 year ago

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

There is an old drug that might have lots of new tricks in its sleeve.

Zacks Investment Research - 1 year ago

Concert Pharmaceuticals (CNCE) announces initiation of multiple-ascending dose phase I study to evaluate its pipeline candidate, CTP-692, as an adjunctive treatment for schizophrenia.

Market Watch - 1 year ago

Shares of Concert Pharmaceuticals Inc. took a sharp afternoon dive Monday, after the biopharmaceutical company said the patent trial and appeal board found that the claims of the patent on its...

About CNCE

Concert Pharmaceuticals operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for the treatment of autoimmune and central nervous system disorders. Its product candidates include CTP-543, which is in Phase III clinical trials for the treatment of alopecia areata; CTP-692, a selective deuterium-modified analog of the endogenous amino acid and D-serine that is in Phase II trials for the treatment of schizophrenia; and AVP-786, a combination of deudextromethorphan and an ultra-low dos... [Read more...]

Industry
Biotechnology
IPO Date
Feb 13, 2014
CEO
Roger Tung
Employees
70
Stock Exchange
NASDAQ
Ticker Symbol
CNCE
Full Company Profile

Financial Performance

In 2019, CNCE's revenue was $1.08 million, a decrease of -89.75% compared to the previous year's $10.51 million. Losses were -$78.17 million, 39.5% more than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for CNCE stock is "Strong Buy." The 12-month stock price forecast is 24.00, which is an increase of 128.35% from the latest price.

Price Target
$24.00
(128.35% upside)
Analyst Consensus: Strong Buy